Clinical trials: Systemic Lupus
Diet Habit, Rheumatologic Disease
Rheumatology Diet Study
This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their…
- Conditions
- Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis
- Trial name
- NCT06339957
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Central Florida
Lupus Erythematosus, Systemic Lupus Erythematosus
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
- Conditions
- Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06294236
- Testing
- SC291
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sana Biotechnology
Lupus Nephritis
Urine Exosomes to Identify Biomarkers for LN
Urine exosomes will be extracted from patients with lupus nephritis, healthy controls, and patients with systemic lupus erythematosus without lupus nephritis.
- Trial name
- NCT04894695
- Testing
- biomarkers detection in different groups
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
This study provides subjects who complete the BEL113750 study and subjects who complete the open-label extension of HGS1006-C1115 (referred to as C1115) Study in Japan the option of continuing treatment with belimumab (10 mg/kg…
- Trial name
- NCT01597622
- Testing
- Belimumab
- Where
- 27 sites in Japan, South Korea
- Volunteers
- 142 people
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus
Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus.
Background: Sleep quality is a key determinant of physical and mental health, with important implications for immune regulation, psychological well-being, and overall quality of life.
- Trial name
- NCT07483541
- Testing
- Adults with systemic lupus erythematosus
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Systemic Lupus Erythematosus
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus
This study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus.
- Trial name
- NCT03219801
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hebei Medical University
Lupus Arthritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams [mg] and 1 mg) in participants with active lupus arthritis.
- Trial name
- NCT01085084
- Testing
- Laquinimod
- Where
- 22 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
This was a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF…
- Trial name
- LUNAR (NCT00282347)
- Testing
- Rituximab, Mycophenolate mofetil, Methylprednisolone
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or…
- Conditions
- SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis
- Trial name
- NCT07193810
- Testing
- CC312
- Where
- China
- Volunteers
- 6 people
- Sponsor
- CytoCares Inc
Lupus Erythematosus, Systemic
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
The purpose of this study is to determine how B cell subsets and autoantibodies are related to disease remission after rituximab treatment in subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT01702038
- Testing
- Rituximab
- Where
- 2 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Erythematosus, Systemic
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs.
- Trial name
- CLEVER-SLE (NCT07659704)
- Testing
- Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center
- Where
- 2 sites in Brazil
- Volunteers
- 16 people
- Sponsor
- University of Sao Paulo
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
The goal of this clinical trial is to evaluate CLBR001 and SWI019 as a treatment for patients with autoimmune disorders, including systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myositis.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06913608
- Testing
- CLBR001 + SWI019
- Sponsor
- Calibr, a division of Scripps Research
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate…
- Conditions
- Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis
- Trial name
- COVBIRD (NCT05236491)
- Testing
- COVID-19 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 287 people
- Sponsor
- Paul R Fortin
Lupus Nephritis
LUPKYNIS Drug-use Results Survey
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
- Trial name
- NCT07053891
- Testing
- Voclosporin (LUPKYNIS)
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Serologically Active Adult Systemic Lupus Erythematosus
Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)
EBV has been implicated in pathogeny of SLE with increase in EBV sero-prevalence, defective control in EBV infection and altered both B and T immune responses to this virus The main objective of this pilot proof-of-concept (POC)…
- Trial name
- LUPUS CTL EBV (NCT02677688)
- Testing
- Autologous EBV specific CTL infusion
- Where
- 3 sites in France
- Volunteers
- 9 people
- Sponsor
- Nantes University Hospital
Systemic Lupus Erythematosus
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms.
- Trial name
- SHIELD (NCT05799378)
- Testing
- Hydroxychloroquine
- Where
- 12 sites in United States
- Volunteers
- 330 people
- Sponsor
- NYU Langone Health
Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
The primary purpose of the study is to evaluate the efficacy of BIIB059 (litifilimab) in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement…
- Trial name
- LILAC (NCT02847598)
- Testing
- BIIB059 (litifilimab)
- Where
- 128 sites in United States, Argentina and 10 more
- Volunteers
- 264 people
- Sponsor
- Biogen
Systemic Lupus Erythematosus
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to…
- Trial name
- NCT04179032
- Testing
- Belimumab
- Where
- 11 sites in United States, Argentina and 5 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus, Lichen Planus
Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus
Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature.
- Trial name
- NCT04356014
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Montpellier
Systemic Lupus Erythematosus
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants…
- Trial name
- SIRIUS-SLE 1 (NCT05639114)
- Testing
- Ianalumab
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.